Logo of Biovectra, a part of Agilent, featuring stylized geometric design with purple and yellow elements against a black background.

CATALOGUE

CATALOGUE

Explore Superior Quality Bioreagents from BIOVECTRA

The highest quality of reagents available including DTT, DHAA, and more!

At BIOVECTRA, we’re committed to advancing your bioprocessing capabilities, and our selection of high-quality bioprocessing reagents is here to make it happen. Whether you’re in the early stages of research or managing large-scale manufacturing operations, our reagents deliver unparalleled performance and reliability.

Benefits of our Bioreagents Include:

  • Variety of grades available to meet all needs, including cGMP-grade to support cGMP manufacturing
  • Available in a range of sizes (gram to multi-kg scale)
  • North American based multi-scale organic synthesis facility (50-1,000 gallon scale reactors)

Complete the form to view our full selection of offerings including DTT, DHAA, TCEP, IPTG, and more. 

Cover of Bioreagents Catalogue, February 2024, by Biovectra, a part of Agilent. Features schematic equipment illustrations and corporate branding.

About Us

With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.

The image features the phrase "We Care" in white with a purple and yellow heart shape, representing a focus on empathy and support.

Contact Us

Toll Free: +1 (866) 883-2872
Phone: +1 (902) 566-9116
Fax: +1 (902) 628-2045

11 Aviation Avenue,
Charlottetown, PE, C1E 0A1
Canada

Logo featuring "BIOVECTRA" in purple text with a blue and yellow abstract design, and the phrase "A part of Agilent" below.
Facebook Linkedin

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors